Clinical Trials Browser

INDUSTRY × sintilimab × Lymphoid × Clear all

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse